David Van Bibber calls his neuroendocrine cancer diagnosis a blessing in disguise.it. Since his 2010 diagnosis at the age of 32, David’s priorities and perspectives have changed. As a result, he has invested more deeply in his health, his family, and his community. Now he is reaping the rewards of that investment and finding daily joy in his life.
Finding hope and motivation in a dark place, a young NET patient describes her life leading up and following peptide receptor radionuclide therapy (PRRT).
The Neuroendocrine Tumor Research Foundation (NETRF) has invested more than $1.5 million in advancing a precision form of radiation therapy for NETs called Peptide Receptor
Two NETRF-funded researchers received Career Development Awards at the 2018 annual meeting of the American Society of Clinical Oncology (ASCO), one of the largest and
https://www.youtube.com/watch?v=k1906SABias The Neuroendocrine Tumor Research Foundation (NETRF) has invested more than $1.5 million in advancing a precision form of radiation therapy for NETs called Peptide Receptor
Can an epigenetic enzyme under the right conditions contribute to the growth of cancer cells? If so, what happens if the enzyme is removed? Can
Having arrived seven weeks ago as the new Chief Development Officer, I have been so inspired by the team spirit of NETRF. From our dedicated
NETRF announces the appointment of Susan Payson as Chief Development Officer. In this new position, Susan will work to expand NETRF’s base of support to
The first step in curing a disease is understanding it. Unfortunately, there is a lot we still don’t know about small-intestinal NETs (SI-NETs). That’s why
by Ronny Allan, NET Patient Activist Doctors and scientists are always looking for better ways to care for patients with cancer; they are looking for
